Provides clinical validation for ACM Biolab’s Tunable Platform (“ATP™”), ACM Biolab’s proprietary polymer-based delivery platform ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data ACM is in partnering…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.